TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01026597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN727
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5 IV cohorts (dose 1, 2, 3, 4, and 5)
Study: NCT03808857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB226
Description: GB226 is administrated at the dose of 3mg/kg, once per 2 weeks (±3 days), and distributed in 100ml of 0.9% sodium chloride solution. The concentration of GB226 shall be strictly controlled at 1mg/ml\~10mg/ml, the duration is 60 min (±10 min) for the first infusion of the drug, and can be reduced to 30 min (±10 min) for the subsequent infusion of the drug if there is infusion related adverse reaction.
Study: NCT02339207

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-335 matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Study: NCT04324320

Intervention type: DIAGNOSTIC_TEST
Intervention: medical assessment
Description: medical assessment includes the collection of~* sociodemographic data~* anthropometric data (weight, height, body mass index)~* medical data~* psycho-oncologic basis assessment (PO-BADO questionnaire)~* pain assessment (VAS: visual analogue scale)~* 3 functional tests:~  * handgrip strength~ * 6 Minute Walking Test~ * Timed Get up and Go Test

Intervention type: DIAGNOSTIC_TEST
Intervention: psychological assessment
Description: psychological assessment includes several standardized screening and assessment questionnaires and tools:~* quality of life: SF-36~* anxiety, depression, stress: Hospital Anxiety and Depression Scale (HADS-D)~* subjective stress perception: Perceived Stress Scale (PSS-10)~* resilience: resilience scale (RS-13)~* fatigue: Brief Fatigue Inventory (BFI)~* disability related to pain: Pain Disability Index (PDI)~* workability: Work Ability Index - short version (WAI-K)~* psychological assessment based on the checklist of the International Diagnoses (IDCL) for ICD-10 and the ICD-10 checklist of symptoms for psychological disorders (SCL))
Study: NCT00215956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation
Description: Preoperative radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
Study: NCT00771602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
Study: NCT02104102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Mirror Therapy, which is based on the activation of mirror neurons from the illusion generated by viewing the reflection of a member in a mirror, that is, intended to facilitate the movement through the practice of bilateral symmetric activities, since it is able to stimulate cortical plasticity, promoting reversal of the decrease and the reestablishment of motor function.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Description: Hands movements.
Study: NCT03748667

Intervention type: DIAGNOSTIC_TEST
Intervention: White light endoscopy (WLE)
Description: Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.

Intervention type: DIAGNOSTIC_TEST
Intervention: NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)
Description: Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.
Study: NCT04399005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: after-each-case room disinfection
Description: After-each-case room disinfection was defined as after completing each case.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: daily room disinfection
Description: Daily room disinfection was defined as disinfection after completing 8 non-general anesthesia gastroscopy or 4 general anesthesia gastroscopy.
Study: NCT04549441

Intervention type: PROCEDURE
Intervention: Distal radius fracture plating surgery
Description: We performed open reduction and plating surgery for the distal radius fracture.

Intervention type: PROCEDURE
Intervention: Distal radius fracture plating surgery
Description: We performed open reduction and plating surgery for the distal radius fracture.
Study: NCT00762788

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: 1 week extended wear contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A
Description: 1 week extended wear contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: 1 week extended wear contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: 1 week extended wear contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A
Description: 1 week extended wear contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: 1 week extended wear contact lens
Study: NCT04039269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative video information

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative video information
Study: NCT01625182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod 0.5 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Matching placebo capsules
Study: NCT01235819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Exenatide Sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg per day oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Exenatide 10 micrograms daily twice
Study: NCT01285089

Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices
Study: NCT04163380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest
Study: NCT00787722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A medication used as chemotherapy and to suppress the immune system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rATG
Description: A rabbit polyclonal antibody to lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
Study: NCT04163380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest
Study: NCT00787722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: A corticosteroid medication used to suppress the immune system and decrease inflammation
Study: NCT04199715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heplisav-B
Description: This is an FDA-approved vaccine for Hepatitis B that is made by Dynavax Technologies.
Study: NCT04061629

Intervention type: DEVICE
Intervention: Cuffed ETT
Description: Cuffed endotracheal tube.

Intervention type: DEVICE
Intervention: Cuffed ETT
Description: Cuffed endotracheal tube.

Intervention type: DEVICE
Intervention: Cuffed ETT
Description: Cuffed endotracheal tube.
Study: NCT06109688

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Lactoferrin
Description: Orally intake 1 sachet per day for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Orally intake 1 sachet per day for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution.
Study: NCT02574208

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HIV testing by ELISA
Description: HIV testing randomized between ELISA or rapid test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIV testing by rapid test
Description: HIV testing randomized between ELISA or rapid test
Study: NCT02967887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin and 5-fluorouracil
Description: Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
Study: NCT04407520

Intervention type: OTHER
Intervention: No patient treatment is associated with the study
Description: No patient treatment is associated with the study.
Study: NCT03669679

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast reduction
Description: breast reduction surgery for breast hypertrophy using either superomedial or inferior pedicle technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast reduction
Description: breast reduction surgery for breast hypertrophy using either superomedial or inferior pedicle technique
Study: NCT00546273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI
Description: dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo of the vaccine RUTI
Description: placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
Study: NCT00820092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xerecept 1.0
Description: 24 hour infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xerecept 2.0
Description: 24 hour infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xerecept 3.0
Description: 24 hour infusion
Study: NCT00429299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Arm B 1250mg/d PO Arm C 750mg/d PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib
Description: Arm B 1250mg/d PO Arm C 750mg/d PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80mg/sqm 1 hour infusion for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80mg/sqm 1 hour infusion for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80mg/sqm 1 hour infusion for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 600mg/sqm iv day 1 q21 days for four coursess

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 600mg/sqm iv day 1 q21 days for four coursess

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 600mg/sqm iv day 1 q21 days for four coursess

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidoxorubicin
Description: 75mg/sqm iv day 1 q21 days for four courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidoxorubicin
Description: 75mg/sqm iv day 1 q21 days for four courses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidoxorubicin
Description: 75mg/sqm iv day 1 q21 days for four courses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600mg/sqm day 1 q21 days for four courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600mg/sqm day 1 q21 days for four courses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600mg/sqm day 1 q21 days for four courses
Study: NCT04472741

Intervention type: DEVICE
Group type: OTHER
Intervention: difference between colonoscopes
Description: patients have been randomly assigned for colonoscopy with FUSE or HD SFV endoscopes with or without Endocuff

Intervention type: DEVICE
Group type: OTHER
Intervention: difference between colonoscopes
Description: patients have been randomly assigned for colonoscopy with FUSE or HD SFV endoscopes with or without Endocuff

Intervention type: DEVICE
Group type: OTHER
Intervention: difference between colonoscopes
Description: patients have been randomly assigned for colonoscopy with FUSE or HD SFV endoscopes with or without Endocuff
Study: NCT04241731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed 2.5mg / m2, intravenous infusion for 15min, d1,q2w.
Study: NCT00873093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Given IM 6000 IU/m2/dose Days 2 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Given IM 6000 IU/m2/dose Days 2 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Given IM 6000 IU/m2/dose Days 2 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Given IM 6000 IU/m2/dose Days 2 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Given IM 6000 IU/m2/dose Days 2 and 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV 60 mg/m2/dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV 60 mg/m2/dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV 60 mg/m2/dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV 60 mg/m2/dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV 60 mg/m2/dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22
Study: NCT04241731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500mg / kg, intravenous drip over 120min, d1,q2w.
Study: NCT00635284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-009
Description: nab-rapamycin
Study: NCT00726557

Intervention type: BIOLOGICAL
Intervention: PegIntron (pegylated interferon alfa-2b; SCH 54031)
Description: PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
Study: NCT03818581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: 10-mg or 20-mg Suvorexant capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study: NCT00840281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil® 500 mg tablets
Description: 1 x 500 mg, single-dose fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg Tablets
Description: 1 x 500 mg, single-dose fasting
Study: NCT00734019

Intervention type: DEVICE
Intervention: P.F.C. Sigma Knee
Description: Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
Study: NCT03820427

Intervention type: DIAGNOSTIC_TEST
Intervention: impulse oscillometry
Description: impulse oscillometry

Intervention type: DIAGNOSTIC_TEST
Intervention: impulse oscillometry
Description: impulse oscillometry

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout test
Description: multiple breath washout test

Intervention type: DIAGNOSTIC_TEST
Intervention: multiple breath washout test
Description: multiple breath washout test

Intervention type: DIAGNOSTIC_TEST
Intervention: body plethysmography
Description: body plethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: body plethysmography
Description: body plethysmography
Study: NCT02354560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
Study: NCT01305681

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LoFric® catheters during clean intermittent catheterization
Description: LoFric® catheters during clean intermittent catheterization
Study: NCT03687762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy (CT)
Description: The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation (MM)
Description: Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activation Skills (AS)
Description: Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.